Montrose became Houston’s LGBTQ+ stronghold in the 20th century, but as the city grows, the queer community is expanding ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

The European Medicines Agency's safety committee said on Friday Novo Nordisk's popular weight-loss and diabetes drugs Wegovy ...

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.